Skip to main content
Premium Trial:

Request an Annual Quote

Roka Bioscience Plans 1-for-10 Reverse Stock Split

NEW YORK (GenomeWeb) – Food safety test developer Roka Bioscience announced today that it will effect a 1-for-10 reverse split of its common stock in an effort to regain compliance with the Nasdaq's $1 minimum bid price requirement.

The reverse split, which was approved by shareholders at the company's annual meeting earlier this year, will reduce the number of outstanding shares to about 1.8 million from 17.8 million. The move will affect all Roka shares and proportionally reduce the number of common shares underlying its outstanding Series A preferred stock, warrants, and equity awards.

"Each stockholder's percentage ownership interest and proportional voting power remains unchanged and the rights and privileges of the holders of the company's common stock are unaffected," the company noted in a statement.

The reverse split will take effect at the opening of trading on Oct. 12.

During late morning trading on the Nasdaq, shares of Roka were down 8 percent to $.68.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.